Overview

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Status:
Completed
Trial end date:
2009-12-11
Target enrollment:
Participant gender:
Summary
This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
Phase:
Phase 3
Details
Lead Sponsor:
Optimer Pharmaceuticals LLC
Treatments:
Vancomycin